In these cases, symptoms can persist for several months, especially if the dosage is increased too quickly or if there are other factors at play, such as dietary habits or pre-existing gastrointestinal conditions
Profile 3: Poorly Controlled or Unstable Psychiatric Illness Semaglutide and tirzepatide carry no specific psychiatric black box warning, but the FDA's Adverse Event Reporting System (FAERS) contains post-marketing reports of suicidal ideation associated with GLP-1 agents, prompting the FDA to open a signal evaluation in 2023 [7]
Based on your unique biology, Viome can: Recommend prebiotic-rich foods that support butyrate production, bile acid metabolism, and other GLP-1 supportive pathways Provide supplements with polyphenols and microbiome modulators Deliver lifestyle suggestions aligned with your mitochondrial and gut health scores Disclaimer : While Viomes personalized approach is grounded in science, long-term clinical outcomes for GLP-1-specific interventions are still being researched
In August, Novo Nordisk was